Results 31 to 40 of about 274,289 (156)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)

Pulmonary Circulation, 2022
Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan, Sarfraz A. Saleemi, Ihab Weheba, Abeer Abdelsayed, Maha M. Aleid, Fatima Alzubi, Hamdeia Zaytoun, Nadeen Alharbi   +7 more
doaj   +1 more source

Pulmonary Hypertension [PDF]

Pulmonary Medicine, 2012
Pulmonary hypertension (PH), defined as elevated pulmonary artery pressure, is common in the general population and associated with increased mortality. Accordingly, physicians commonly encounter patients with dyspnea, exercise intolerance, and/or right heart failure who have elevated pulmonary artery systolic pressure (PASP) on echocardiography ...
Ilknur Basyigit, Gulfer Okumus, Serpil Erzurum, Kewal Asosingh, Despina Papakosta   +4 more
openaire   +5 more sources

Tetrahydrobiopterin analogues with NO-dependent pulmonary vasodilator properties [PDF]

, 2011
Reduced NO levels due to the deficiency of tetrahydrobiopterin (BH4) contribute to impaired vasodilation in pulmonary hypertension Due to the chemically unstable nature of BH4 it was hypothesised that oxidatively stable analogues of BR, would be able to ...
Gibson, Colin, Kunuthur, S. P., Milliken, P. H., Suckling, C. J., Wadsworth, R. M.   +4 more
core   +1 more source

The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients

BMC Pulmonary Medicine, 2019
Background Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH).
Iain Armstrong, Catherine Billings, David G. Kiely, Janelle Yorke, Carl Harries, Shaun Clayton, Wendy Gin-Sing   +6 more
doaj   +1 more source

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension

Arthritis Research & Therapy, 2023
Background Patients with systemic sclerosis (SSc) are frequently affected by iron deficiency, particularly those with pulmonary hypertension (PH). The first data indicate the prognostic importance of hypochromic red cells (% HRC) > 2% among patients with
Panagiota Xanthouli, Ojan Gordjani, Nicola Benjamin, Satenik Harutyunova, Benjamin Egenlauf, Alberto M. Marra, Simon Haas, Nicklas Milde, Norbert Blank, Hanns-Martin Lorenz, Christoph Fiehn, Silvia Ulrich, Oliver Distler, Ekkehard Grünig, Christina A. Eichstaedt   +14 more
doaj   +1 more source

Pulmonary hypertension

Nature Reviews Disease Primers
Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to elevated pressures within the pulmonary arteries. Five main groups of pulmonary hypertension are recognized, all defined by a mean pulmonary artery pressure of >20 mmHg: pulmonary arterial hypertension (rare), pulmonary hypertension associated with left-sided ...
Ana Mocumbi, Marc Humbert, Anita Saxena, Zhi-Cheng Jing, Karen Sliwa, Friedrich Thienemann, Stephen L. Archer, Simon Stewart   +7 more
openaire   +3 more sources

Under pressure: pulmonary hypertension associated with left heart disease. [PDF]

, 2015
© ERS 2015.Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common type of PH, but its natural history is not well understood.
Farber, HW, Gibbs, S
core   +2 more sources

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)

Arthritis Research & Therapy, 2019
Objective The objective of this randomized, placebo-controlled, double-blind, parallel group, trial was to assess the effect of ambrisentan on mean pulmonary arterial pressure (mPAP) in patients with systemic sclerosis (SSc) and mildly elevated pulmonary
Zixuan Pan, Alberto M. Marra, Nicola Benjamin, Christina A. Eichstaedt, Norbert Blank, Eduardo Bossone, Antonio Cittadini, Gerry Coghlan, Christopher P. Denton, Oliver Distler, Benjamin Egenlauf, Christine Fischer, Satenik Harutyunova, Panagiota Xanthouli, Hanns-Martin Lorenz, Ekkehard Grünig   +15 more
doaj   +1 more source

Non-infectious pulmonary complications of hematopoietic stem cell transplantation [PDF]

, 2014
Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than infectious complications. Unfortunately, the pathophysiology basis is not completely understood.
Baloglu, Orkun, McArthur, Jennifer, Rowan, Courtney   +2 more
core   +1 more source

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

Pulmonary Circulation, 2018
Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial ...
Nader Chebib, Jean-François Mornex, Julie Traclet, François Philit, Chahera Khouatra, Sabrina Zeghmar, Ségolène Turquier, Vincent Cottin   +7 more
doaj   +1 more source